{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:31:54Z","timestamp":1793349114949,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:00:00Z","timestamp":1793318400000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017633","name":"Shanghai Anti Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018573","name":"Sun Yat-Sen University Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijrobp.2026.10.015","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:19:00Z","timestamp":1792718340000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concurrent Versus Sequential Postoperative Radiotherapy and CDK4\/6 Inhibitors in Breast Cancer with Positive Regional Nodes: A Multi-Center Safety and Toxicity Study"],"prefix":"10.1016","author":[{"given":"Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxiu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhuoFei","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurou","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-1153","authenticated-orcid":false,"given":"Xiaobo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ijrobp.2026.10.015_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"Journal of the National Cancer Institute"},{"issue":"24","key":"10.1016\/j.ijrobp.2026.10.015_bib0002","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"18","key":"10.1016\/j.ijrobp.2026.10.015_bib0003","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"The New England journal of medicine"},{"issue":"32","key":"10.1016\/j.ijrobp.2026.10.015_bib0004","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.ijrobp.2026.10.015_bib0005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.ijrobp.2026.10.015_bib0006","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.4161\/cc.26130","article-title":"CDK4\/6-inhibiting drug substitutes for p21 and p16 in snescence: duration of cell cycle arrest and MTOR activity determine geroconversion","volume":"12","author":"Leontieva","year":"2013","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.ijrobp.2026.10.015_bib0007","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2024.01.025","article-title":"Dual Inhibition of CDK4\/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs","volume":"166","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.ijrobp.2026.10.015_bib0008","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1016\/j.molcel.2023.10.016","article-title":"CDK4\/6 inhibitor-mediated cell overgrowth triggers osmotic and replication stress to promote senescence","volume":"83","author":"Crozier","year":"2023","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.ijrobp.2026.10.015_bib0009","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"20","key":"10.1016\/j.ijrobp.2026.10.015_bib0010","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.ijrobp.2026.10.015_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102212","article-title":"BET inhibitor and CDK4\/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair","volume":"51","author":"Chi","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ijrobp.2026.10.015_bib0012","doi-asserted-by":"crossref","first-page":"11107","DOI":"10.2147\/OTT.S234221","article-title":"CDK4\/6 Inhibitor Palbociclib Amplifies the Radiosensitivity to Nasopharyngeal Carcinoma Cells via Mediating Apoptosis and Suppressing DNA Damage Repair","volume":"12","author":"Xie","year":"2019","journal-title":"OncoTargets and therapy"},{"key":"10.1016\/j.ijrobp.2026.10.015_bib0013","article-title":"Radiosensitizing effects of CDK4\/6 inhibitors in hormone receptor-positive and HER2-negative breast cancer mediated downregulation of DNA repair mechanism and NF-kappaB-signaling pathway","volume":"49","author":"Yang","year":"2024","journal-title":"Transl Oncol. Nov"},{"issue":"11","key":"10.1016\/j.ijrobp.2026.10.015_bib0014","first-page":"1519","article-title":"Inhibition of DNA damage repair by the CDK4\/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth","volume":"18","author":"Hashizume","year":"2016","journal-title":"Neuro-oncology"},{"issue":"7","key":"10.1016\/j.ijrobp.2026.10.015_bib0015","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/ijc.34562","article-title":"Outcomes and toxicity of concurrent CDK4\/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer","volume":"153","author":"Beddok","year":"2023","journal-title":"International journal of cancer"},{"issue":"2","key":"10.1016\/j.ijrobp.2026.10.015_bib0016","article-title":"Unexpected toxicity of CDK4\/6 inhibitor palbociclib and radiotherapy","volume":"5","author":"van Aken","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.ijrobp.2026.10.015_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102586","article-title":"Safety profile of cyclin-dependent kinase (CDK) 4\/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis","volume":"119","author":"Becherini","year":"2023","journal-title":"Cancer treatment reviews"},{"issue":"7","key":"10.1016\/j.ijrobp.2026.10.015_bib0018","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"34","key":"10.1016\/j.ijrobp.2026.10.015_bib0019","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"20","key":"10.1016\/j.ijrobp.2026.10.015_bib0020","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer","volume":"379","author":"Turner","year":"2018","journal-title":"The New England journal of medicine"},{"issue":"14","key":"10.1016\/j.ijrobp.2026.10.015_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143658","article-title":"Cyclin-Dependent Kinase 4\/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force \"Dermatology for Cancer Patients\" International Study","volume":"15","author":"Sollena","year":"2023","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.ijrobp.2026.10.015_bib0022","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14740338.2023.2288147","article-title":"Interstitial lung disease and CDK4\/6 inhibitors in the treatment of breast cancer","volume":"22","author":"Schlam","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.ijrobp.2026.10.015_bib0023","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/2042098617722516","article-title":"Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis","volume":"8","author":"Shohdy","year":"2017","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"10.1016\/j.ijrobp.2026.10.015_bib0024","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/14740338.2024.2348566","article-title":"Hematological toxicity of cyclin-dependent kinase 4\/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study","volume":"24","author":"Ding","year":"2025","journal-title":"Expert Opin Drug Saf. Feb"},{"issue":"3","key":"10.1016\/j.ijrobp.2026.10.015_bib0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijrobp.2022.07.005","article-title":"Radiation Therapy With Cyclin-Dependent Kinase 4\/6 Inhibitors: A Multi-institutional Safety and Toxicity Study","volume":"114","author":"Al-Rashdan","year":"2022","journal-title":"International journal of radiation oncology, biology, physics"},{"issue":"1","key":"10.1016\/j.ijrobp.2026.10.015_bib0026","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"The Lancet Oncology"},{"issue":"23","key":"10.1016\/j.ijrobp.2026.10.015_bib0027","first-page":"2220","article-title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer","volume":"390","author":"Li","year":"2024","journal-title":"The New England journal of medicine"},{"issue":"4","key":"10.1016\/j.ijrobp.2026.10.015_bib0028","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"The Lancet Oncology"},{"issue":"2","key":"10.1016\/j.ijrobp.2026.10.015_bib0029","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12282-022-01422-5","article-title":"Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4\/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study","volume":"30","author":"Kawamoto","year":"2023","journal-title":"Breast Cancer"},{"issue":"31","key":"10.1016\/j.ijrobp.2026.10.015_bib0030","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.20.01363","article-title":"Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial","volume":"38","author":"Offersen","year":"2020","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.ijrobp.2026.10.015_bib0031","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"The Lancet Oncology"},{"issue":"3","key":"10.1016\/j.ijrobp.2026.10.015_bib0032","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","article-title":"Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial","volume":"20","author":"Wang","year":"2019","journal-title":"The Lancet Oncology"},{"issue":"31","key":"10.1016\/j.ijrobp.2026.10.015_bib0033","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.20.01024","article-title":"Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China","volume":"38","author":"Wang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.10.015_bib0034","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.radonc.2022.10.023","article-title":"Safety of CDK4\/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer","volume":"177","author":"Visani","year":"2022","journal-title":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"},{"key":"10.1016\/j.ijrobp.2026.10.015_bib0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2021.11.025","article-title":"Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial","volume":"162","author":"Peuker","year":"2022","journal-title":"European journal of cancer (Oxford, England : 1990)"},{"key":"10.1016\/j.ijrobp.2026.10.015_bib0036","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.canlet.2019.02.049","article-title":"P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy","volume":"451","author":"Fernandez-Aroca","year":"2019","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.ijrobp.2026.10.015_bib0037","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154402","article-title":"RB expression confers sensitivity to CDK4\/6 inhibitor-mediated radiosensitization across breast cancer subtypes","volume":"7","author":"Pesch","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ijrobp.2026.10.015_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.740002","article-title":"Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation","volume":"11","author":"Jost","year":"2021","journal-title":"Frontiers in oncology"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626043853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626043853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:51:58Z","timestamp":1793346718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626043853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"alternative-id":["S0360301626043853"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.10.015","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concurrent Versus Sequential Postoperative Radiotherapy and CDK4\/6 Inhibitors in Breast Cancer with Positive Regional Nodes: A Multi-Center Safety and Toxicity Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}